Table 3.
Treatment Modalities and Specifications During Follow-Up in Patients with Acute CSC
| Study Eyes | ||||
|---|---|---|---|---|
| Entire Cohort | Cases with <12 Months Follow-Up | Cases with ≥12 Months Follow-Up | ||
| Eyes not treated at first episode [wait-and-see approach] (%) | 154 (52) | 47 (50) | 107 (51) | |
| Eyes treated at first episode [early-treatment group] (%) | 141 (48) | 47 (50) | 94 (49) | |
| Treatment specifications at first episode (%) | PDTa | 134 (95) | 43 (92) | 91 (97) |
| Conventional laser | 3 (2) | 2 (4) | 1 (1) | |
| SML | 4 (3) | 2 (4) | 2 (2) | |
| Eyes with additional treatments after first episode (%) | 23 (8) | 1 (1) | 22 (11) | |
| Average number of retreatments (range) | 1 (1–2) | 2 (2–2) | 1 (1–2) | |
| Re-treatment specifications (%) | PDTb | 71 (93) | 1 (50) | 70 (94) |
| Conventional laser | 2 (3) | 0 | 2 (3) | |
| SML | 3 (4) | 1 (50) | 2 (3) | |
Notes: a56 (42%) eyes received half-dose PDT, 67 (50%) eyes received half-time PDT, and 11 eyes (8%) had unknown PDT settings; mean spot size: 1746±1109 µm. b28 (39%) eyes received half-dose PDT, 40 (57%) eyes received half-time PDT, and 3 (4%) eyes had full PDT settings; mean spot size: 2066±1256 µm.
Abbreviations: CSC, central serous chorioretinopathy; PDT, photodynamic therapy; SML, subthreshold micropulse diode laser.